Vis enkel innførsel

dc.contributor.authorSinning, Christoph
dc.contributor.authorMakarova, Nataliya
dc.contributor.authorVölzke, Henry
dc.contributor.authorSchnabel, Renate B.
dc.contributor.authorOjeda, Francisco
dc.contributor.authorDörr, Marcus
dc.contributor.authorFelix, Stephan B.
dc.contributor.authorKoenig, Wolfgang
dc.contributor.authorPeters, Annette
dc.contributor.authorRathmann, Wolfgang
dc.contributor.authorSchöttker, Ben
dc.contributor.authorBrenner, Hermann
dc.contributor.authorVeronesi, Giovanni
dc.contributor.authorCesana, Giancarlo
dc.contributor.authorBrambilla, Paolo
dc.contributor.authorPalosaari, Tarja
dc.contributor.authorKuulasmaa, Kari
dc.contributor.authorNjølstad, Inger
dc.contributor.authorMathiesen, Ellisiv B.
dc.contributor.authorWilsgaard, Tom
dc.contributor.authorBlankenberg, Stefan
dc.contributor.authorSöderberg, Stefan
dc.contributor.authorFerrario, Marco M.
dc.contributor.authorThorand, Barbara
dc.date.accessioned2021-12-22T13:11:49Z
dc.date.available2021-12-22T13:11:49Z
dc.date.issued2021-11-15
dc.description.abstractBackground: Biomarkers may contribute to improved cardiovascular risk estimation. Glycated hemoglobin A<sub>1c</sub> (HbA<sub>1c</sub>) is used to monitor the quality of diabetes treatment. Its strength of association with cardiovascular outcomes in the general population remains uncertain. This study aims to assess the association of HbA<sub>1c</sub> with cardiovascular outcomes in the general population.<p> <p>Methods: Data from six prospective population-based cohort studies across Europe comprising 36,180 participants were analyzed. HbA<sub>1c</sub> was evaluated in conjunction with classical cardiovascular risk factors (CVRFs) for association with cardiovascular mortality, cardiovascular disease (CVD) incidence, and overall mortality in subjects without diabetes (N=32,496) and with diabetes (N=3684).<p> <p>Results: Kaplan–Meier curves showed higher event rates with increasing HbA<sub>1c</sub> levels (log-rank-test: p<0.001). Cox regression analysis revealed signifcant associations between HbA<sub>1c</sub> (in mmol/mol) in the total study population and the examined outcomes. Thus, a hazard ratio (HR) of 1.16 (95% confdence interval (CI) 1.02–1.31, p=0.02) for cardiovascular mortality, 1.13 (95% CI 1.03–1.24, p=0.01) for CVD incidence, and 1.09 (95% CI 1.02–1.17, p=0.01) for overall mortality was observed per 10 mmol/mol increase in HbA<sub>1c</sub>. The association with CVD incidence and overall mortality was also observed in study participants without diabetes with increased HbA<sub>1c</sub> levels (HR 1.12; 95% CI 1.01–1.25, p=0.04) and HR 1.10; 95% CI 1.01–1.20, p=0.02) respectively. HbA<sub>1c</sub> cut-of values of 39.9 mmol/mol (5.8%), 36.6 mmol/mol (5.5%), and 38.8 mmol/mol (5.7%) for cardiovascular mortality, CVD incidence, and overall mortality, showed also an increased risk.<p> <p>Conclusions: HbA<sub>1c</sub> is independently associated with cardiovascular mortality, overall mortality and cardiovascular disease in the general European population. A mostly monotonically increasing relationship was observed between HbA<sub>1c</sub> levels and outcomes. Elevated HbA<sub>1c</sub> levels were associated with cardiovascular disease incidence and overall mortality in participants without diabetes underlining the importance of HbA<sub>1c</sub> levels in the overall population.en_US
dc.identifier.citationSinning, Makarova, Völzke, Schnabel, Ojeda, Dörr, Felix, Koenig, Peters, Rathmann, Schöttker, Brenner, Veronesi, Cesana, Brambilla, Palosaari, Kuulasmaa, Njølstad, Mathiesen, Wilsgaard, Blankenberg, Söderberg, Ferrario, Thorand. Association of glycated hemoglobin A1c levels with cardiovascular outcomes in the general population: results from the BiomarCaRE (Biomarker for Cardiovascular Risk Assessment in Europe) consortium. Cardiovascular Diabetology. 2021;20:223:1-13en_US
dc.identifier.cristinIDFRIDAID 1962331
dc.identifier.doi10.1186/s12933-021-01413-4
dc.identifier.issn1475-2840
dc.identifier.urihttps://hdl.handle.net/10037/23486
dc.language.isoengen_US
dc.publisherBMCen_US
dc.relation.journalCardiovascular Diabetology
dc.relation.projectIDinfo:eu-repo/grantAgreement/EC/FP5/QLG2-CT-2002-01254/Finland/Genome-wide analyses of european twin and population cohorts to identify genes in common diseases/GENOMEUTWIN/en_US
dc.relation.projectIDinfo:eu-repo/grantAgreement/EC/FP7/278913/Germany/Biomarker for Cardiovascular Risk Assessment in Europe/BIOMARCARE/en_US
dc.relation.projectIDinfo:eu-repo/grantAgreement/EC/FP7/242244/Greece/Consortium on Health and Ageing: Network of Cohorts in Europe and the United States/CHANCES/en_US
dc.relation.projectIDinfo:eu-repo/grantAgreement/EC/H2020-EU.3.1.5./825903/Spain/An EU-Canada joint infrastructure for next-generation multi-Study Heart research/euCanSHare/en_US
dc.relation.projectIDinfo:eu-repo/grantAgreement/EC/H2020-EU.3.1.2./847770/Germany/DIGITAL, RISK-BASED SCREENING FOR ATRIAL FIBRILLATION IN THE EUROPEAN COMMUNITY/AFFECT-EU/en_US
dc.relation.projectIDinfo:eu-repo/grantAgreement/EC/?/BMH4-CT98-3183/?/?/?/en_US
dc.relation.projectIDinfo:eu-repo/grantAgreement/EC/FP7/201413/Finland/European Network for Genetic and Genomic Epidemiology/ENGAGE/en_US
dc.rights.accessRightsopenAccessen_US
dc.rights.holderCopyright 2021 The Author(s)en_US
dc.subjectVDP::Medical disciplines: 700::Health sciences: 800::Community medicine, Social medicine: 801en_US
dc.subjectVDP::Medisinske Fag: 700::Helsefag: 800::Samfunnsmedisin, sosialmedisin: 801en_US
dc.titleAssociation of glycated hemoglobin A1c levels with cardiovascular outcomes in the general population: results from the BiomarCaRE (Biomarker for Cardiovascular Risk Assessment in Europe) consortiumen_US
dc.type.versionpublishedVersionen_US
dc.typeJournal articleen_US
dc.typeTidsskriftartikkelen_US
dc.typePeer revieweden_US


Tilhørende fil(er)

Thumbnail

Denne innførselen finnes i følgende samling(er)

Vis enkel innførsel